Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

novartis ag - NVS

NVS

Close Chg Chg %
128.64 -0.58 -0.45%

Closed Market

128.06

-0.58 (0.45%)

Volume: 986.07K

Last Updated:

Sep 9, 2025, 3:59 PM EDT

Trade Now

Company Overview: novartis ag - NVS

NVS Key Data

Open

$128.30

 Day Range

127.90 - 128.58

52 Week Range

96.06 - 130.46

 Market Cap

$244.24B

Shares Outstanding

1.90B

 Public Float

1.90B

Beta

0.62

 Rev. Per Employee

N/A

P/E Ratio

18.51

 EPS

$6.95

Yield

254.61%

 Dividend

$3.28

EX-DIVIDEND DATE

Mar 12, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.15M

  

NVS Performance

1 Week
 
 -0.79%
 
1 Month
 
 10.16%
 
3 Months
 
 7.75%
 
1 Year
 
 11.28%
 
5 Years
 
 51.10%
 

NVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 25
Full Ratings ➔

About novartis ag - NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NVS At a Glance

Novartis AG
Lichtstrasse 35
Basel, Basel-Stadt (Basle Town) 4056
Phone 41-61-324-11-11 Revenue 50.29B
Industry Pharmaceuticals: Major Net Income 11.93B
Sector Health Technology 2024 Sales Growth 10.276%
Fiscal Year-end 12 / 2025 Employees 75,883
View SEC Filings

NVS Valuation

P/E Current 18.514
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 16.457
Price to Sales Ratio 3.938
Price to Book Ratio 4.364
Price to Cash Flow Ratio 11.246
Enterprise Value to EBITDA 10.05
Enterprise Value to Sales 4.293
Total Debt to Enterprise Value 0.145

NVS Efficiency

Revenue/Employee 662,711.549
Income Per Employee 157,271.67
Receivables Turnover 6.125
Total Asset Turnover 0.478

NVS Liquidity

Current Ratio 1.035
Quick Ratio 0.836
Cash Ratio 0.469

NVS Profitability

Gross Margin 74.531
Operating Margin 30.66
Pretax Margin 27.184
Net Margin 23.732
Return on Assets 11.334
Return on Equity 26.312
Return on Total Capital 15.848
Return on Invested Capital 17.855

NVS Capital Structure

Total Debt to Total Equity 70.967
Total Debt to Total Capital 41.509
Total Debt to Total Assets 29.278
Long-Term Debt to Equity 52.068
Long-Term Debt to Total Capital 30.455
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novartis Ag - NVS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
51.63B 50.64B 45.60B 50.29B
Sales Growth
+5.47% -1.90% -9.95% +10.28%
Cost of Goods Sold (COGS) incl D&A
15.87B 15.34B 12.62B 12.81B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.43B 5.46B 8.31B 6.07B
Depreciation
1.53B 1.47B 1.27B 1.19B
Amortization of Intangibles
3.90B 3.99B 7.03B 4.88B
COGS Growth
+4.31% -3.35% -17.72% +1.50%
Gross Income
35.76B 35.31B 32.98B 37.48B
Gross Income Growth
+5.99% -1.26% -6.58% +13.63%
Gross Profit Margin
+69.27% +69.72% +72.33% +74.53%
2021 2022 2023 2024 5-year trend
SG&A Expense
24.43B 23.18B 20.87B 22.06B
Research & Development
9.54B 8.90B 8.25B 9.51B
Other SG&A
14.89B 14.28B 12.61B 12.56B
SGA Growth
+6.39% -5.09% -9.99% +5.74%
Other Operating Expense
- (269.00M) (162.32M) 209.75M
Unusual Expense
684.00M 4.51B 3.61B 1.92B
EBIT after Unusual Expense
10.92B 7.77B 8.29B 13.49B
Non Operating Income/Expense
785.00M 1.66B 1.75B 1.21B
Non-Operating Interest Income
71.00M 379.74M 629.24M 567.68M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
905.00M 1.03B 876.12M 1.04B
Interest Expense Growth
-2.32% +14.14% -15.19% +18.30%
Gross Interest Expense
909.00M 1.04B 879.13M 1.04B
Interest Capitalized
4.00M 5.01M 3.01M 5.00M
Pretax Income
10.80B 8.40B 9.17B 13.67B
Pretax Income Growth
+16.61% -22.24% +9.20% +49.10%
Pretax Margin
+20.92% +16.58% +20.11% +27.18%
Income Tax
2.12B 1.42B 552.97M 1.70B
Income Tax - Current - Domestic
958.00M 618.20M 1.14B 896.49M
Income Tax - Current - Foreign
1.47B 1.46B 1.29B 1.49B
Income Tax - Deferred - Domestic
(23.00M) 142.28M (356.27M) 244.86M
Income Tax - Deferred - Foreign
(286.00M) (798.55M) (1.53B) (926.48M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
24.02B 6.97B 8.60B 11.93B
Minority Interest Expense
- (3.00M) 4.01M (2.00M)
Net Income
24.02B 6.97B 8.60B 11.93B
Net Income Growth
+195.82% -70.99% +23.39% +38.79%
Net Margin Growth
+46.53% +13.76% +18.86% +23.73%
Extraordinaries & Discontinued Operations
- - - 6.30B
-
Discontinued Operations
- - - 6.30B
-
Net Income After Extraordinaries
24.02B 6.97B 14.90B 11.93B
Preferred Dividends
- - - -
-
Net Income Available to Common
24.02B 6.97B 14.90B 11.93B
EPS (Basic)
10.7112 3.1949 7.176 5.9131
EPS (Basic) Growth
+200.35% -70.17% +124.61% -17.60%
Basic Shares Outstanding
2.24B 2.18B 2.08B 2.02B
EPS (Diluted)
10.6288 3.1719 7.1239 5.8645
EPS (Diluted) Growth
+200.53% -70.16% +124.59% -17.68%
Diluted Shares Outstanding
2.26B 2.20B 2.09B 2.04B
EBITDA
17.03B 17.74B 20.22B 21.48B
EBITDA Growth
-2.04% +4.18% +13.94% +6.27%
EBITDA Margin
+32.99% +35.04% +44.33% +42.72%

Snapshot

Average Recommendation HOLD Average Target Price 124.884
Number of Ratings 25 Current Quarters Estimate 2.246
FY Report Date 09 / 2025 Current Year's Estimate 8.885
Last Quarter’s Earnings 2.42 Median PE on CY Estimate N/A
Year Ago Earnings 7.81 Next Fiscal Year Estimate 9.265
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 7 19 19
Mean Estimate 2.25 1.95 8.88 9.27
High Estimates 2.35 2.03 9.24 10.40
Low Estimate 2.14 1.81 8.30 8.14
Coefficient of Variance 3.53 4.13 2.64 5.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 5
OVERWEIGHT 1 1 1
HOLD 16 16 14
UNDERWEIGHT 1 1 2
SELL 3 3 4
MEAN Hold Hold Hold

Novartis Ag in the News